Drug Actions in Synaptic Transmission Flashcards
Describe the 5 steps involved in neurotransmission. Include the sites where each step takes place.
- neurotransmitter synthesis occurs in the neuron; requires specific precursor molecules to enter across the plasma membrane and rate limiting enzymes
- vesicular storage occurs at the cell body to protect from cytosolic enzymes
- synaptic release occurs at the pre-synaptic plasma membrane via interaction of SNAREs on vesicle and plasma membranes and influx of calcium causing depolarization
- binding to receptor on the pre- or post-synaptic membranes
- termination of action occurs via reuptake (pre-, post- or glial depending on where reuptake receptor is located), diffusion out of synaptic cleft, or metabolic degradation/transformation. Mechanism of termination depends on the drug.
Describe drug targets/actions during NT synthesis.
NEUROTRANSMITTER SYNTHESIS
- inhibition of enzymes involved
- precursor availability (ex: low tryptophan, high AA diet of AA that use the same transporter => reduced serotonin production)
- increase precursor availability to increase neurotransmission
Distinguish between noradrenergic and peptidergic neurotransmission with regard to the 5 steps. How do differences between the 2 processes influence strategies for their pharmacological manipulation?
PEPTIDERGIC STEPS
- NT synthesis: mRNA => rough ER => pre-propeptide => cleavage by peptidases => active neuropeptide
- vesicular storage into large, dense core vesicles; packaging occurs in ER; hard to target
- release requires longer duration of calcium influx b/c dense core vesicles are farther away from synapse; typically are co-released with other NTs when nerve terminal is active; still affected by membrane ion altering drugs
- binding is complex and not well-known; difficult to cross BBB; non-peptide agonists/antagonists have been developed
- termination is mainly by peptidase-mediated degradation; however, peptidases are not specific targets.
DIFFERENCES IN PHARM MANIPULATION
- harder to target vesicles
- similarly affected by calcium influx drugs b/c of co-release
- difficult to get peptide drugs across BBB so must use non-peptide; binding to receptors is not well-known
- hard to target peptidase-mediated termination b/c peptidases are not specific and can cause many side effects
Describe the effects of metyrosine on adrenergic neurotransmission.
INDICATION - HTN
MECHANISM - competitive inhibition of tyrosine hydroxylase (prevents tyrosine => DOPA; reduction of NT)
Describe the effects of reserpine on adrenergic neurotransmission.
INDICATION - HTN
MECHANISM - inhibits VMAT uptake of MAOs (inhibits vesicular transport => reduction of NT)
Describe the effects of bretylium on adrenergic neurotransmission.
INDICATION - ventricular arrhythmia
MECHANISM - inhibits action potential and calcium-dependent vesicular fusion (in NT and NPs; reduction of NT)
Describe the effects of cocaine on adrenergic neurotransmission.
INDICATION - analgesia in surgery
MECHANISM - blocks MAO reuptake receptor (increased NT in synapse)
Describe the effects of tricyclic antidepressants on adrenergic neurotransmission.
INDICATION - depression
MECHANISM - blocks MAO reuptake receptor (increased NT in synapse)
Describe the effects of monoamine oxidase inhibitors (MAOIs) on adrenergic neurotransmission.
INDICATION - depression
MECHANISM - blocks MAO-mediated degradation of NT in cytoplasm after reuptake => increased NT
Describe the effects of SSRIs on adrenergic neurotransmission.
INDICATION - depression
MECHANISM - selectively blocks serotonin reuptake receptors; increased NT
Describe the effects of amphetamines (or ephedrine) on adrenergic neurotransmission.
INDICATION - narcolepsy; ADHD
MECHANISM - reverse MAO reuptake transporters => increased NT
Describe the effects of naloxone/naltrexone on adrenergic neurotransmission.
INDICATION - opioid overdose or addiction
MECHANISM - non-peptide opioid receptor antagonist; decreases NT action
Describe the effects of ACE inhibitors (lisinopril) on adrenergic neurotransmission.
INDICATION - HTN
MECHANISM - inhibits peptide cleavage of angiotensin I to angiotensin II
Describe the effects of phenylephrine on adrenergic neurotransmission.
INDICATION - hypOtension during surgery
MECHANISM - direct agonist of adrenergic receptors; resistant to COMT degradation in synapse; increases NT
Describe the effects of L-DOPA on adrenergic neurotransmission.
INDICATION - parkinson’s
MECHANISM - precursor loading for DOPA decarboxylase conversion of L-DOPA to dopamine; increased NT